Haemonetics Corporation
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-58.3% vs price
Base Case (Median)
-49.7% vs price
Bull Case (75th pct.)
-11.7% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $93.15 | 3.2% | High (40%) |
| PE Comparable | $45.40 | -49.7% | Medium (25%) |
| Growth Trajectory DCF | $36.73 | -59.3% | Medium (20%) |
| Graham Number | $27.83 | -69.2% | Medium (40%) |
| EV/EBITDA | $66.23 | -26.6% | Medium (20%) |
| EV/FCF | $123.45 | 36.8% | Medium (20%) |
| Earnings Power Value | $38.53 | -57.3% | Medium (50%) |
Based on 7 out of 8 methods, HAE appears overvalued at the current price of $90.27. The base case fair value of $45.40 implies 49.7% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.